Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Eyepoint Pharmaceuticals (NASDAQ:EYPT) issued its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01), Fidelity Earnings reports. The company had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $4.81 million. Eyepoint Pharmaceuticals had a negative net margin of 621.04% and a negative return on equity of 165.24%.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

EYPT traded down $0.21 on Friday, hitting $1.45. The company had a trading volume of 1,551,100 shares, compared to its average volume of 422,976. The company’s fifty day moving average price is $2.12 and its 200 day moving average price is $1.71. The company has a current ratio of 5.46, a quick ratio of 5.31 and a debt-to-equity ratio of 1.75. The firm has a market cap of $247.67 million, a P/E ratio of -2.50 and a beta of 1.79. Eyepoint Pharmaceuticals has a 1 year low of $1.19 and a 1 year high of $2.82.

Several brokerages recently issued reports on EYPT. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. ValuEngine lowered shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. B. Riley reduced their price objective on shares of Eyepoint Pharmaceuticals from $5.75 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, September 24th. Guggenheim began coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, September 12th. They issued a “buy” rating and a $4.00 price objective on the stock. Finally, Laidlaw began coverage on shares of Eyepoint Pharmaceuticals in a report on Monday, November 4th. They issued a “buy” rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $3.95.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.

Read More: Trading Strategy Examples and Plans

Earnings History for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Leave a Reply

Your email address will not be published. Required fields are marked *

*